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BACKGROUND. Topical calcipotriol plus 5-fluorouracil (5-FU) combination is an effective
immunotherapy against actinic keratosis (AK), which is a precursor to squamous cell
carcinoma (SCC). However, the long-term effectiveness of calcipotriol plus 5-FU treatment
for SCC prevention is unknown.
METHODS. We performed a blinded prospective cohort study on participants of a
randomized double-blind clinical trial in which a 4-day course of topical calcipotriol plus 5FU combination was compared to Vaseline plus 5-FU (control) for AK treatment. SCC and
basal cell carcinoma (BCC) incidences were assessed at 1, 2, and 3 years after trial.
Tissues were analyzed for calcipotriol plus 5-FU–induced T cell immunity in the skin.
RESULTS. Calcipotriol plus 5-FU–induced tissue-resident memory T (Trm) cell formation in
face and scalp skin associated with significantly higher erythema scores compared with
control (P < 0.01). Importantly, more participants in the test cohort remained SCC-free over
the more than 1,500-day follow-up period (P = 0.0765), and significantly fewer developed
SCC on the treated face and scalp within 3 years (2 of 30 [7%] versus 11 of 40 [28%] in
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BACKGROUND. Topical calcipotriol plus 5-fluorouracil (5-FU) combination is an effective
immunotherapy against actinic keratosis (AK), which is a precursor to squamous cell carcinoma
(SCC). However, the long-term effectiveness of calcipotriol plus 5-FU treatment for SCC prevention
is unknown.
METHODS. We performed a blinded prospective cohort study on participants of a randomized
double-blind clinical trial in which a 4-day course of topical calcipotriol plus 5-FU combination was
compared to Vaseline plus 5-FU (control) for AK treatment. SCC and basal cell carcinoma (BCC)
incidences were assessed at 1, 2, and 3 years after trial. Tissues were analyzed for calcipotriol plus
5-FU–induced T cell immunity in the skin.
RESULTS. Calcipotriol plus 5-FU–induced tissue-resident memory T (Trm) cell formation in face and
scalp skin associated with significantly higher erythema scores compared with control (P < 0.01).
Importantly, more participants in the test cohort remained SCC-free over the more than 1,500day follow-up period (P = 0.0765), and significantly fewer developed SCC on the treated face and
scalp within 3 years (2 of 30 [7%] versus 11 of 40 [28%] in control group, hazard ratio 0.215 [95%
CI: 0.048–0.972], P = 0.032). Accordingly, significantly more epidermal Trm cells persisted in the
calcipotriol plus 5-FU–treated face and scalp skin compared with control (P = 0.0028). There was no
significant difference in BCC incidence between the treatment groups.
CONCLUSION. A short course of calcipotriol plus 5-FU treatment on the face and scalp is associated
with induction of robust T cell immunity and Trm formation against AKs and significantly lowers
the risk of SCC development within 3 years of treatment.
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Introduction
Cutaneous squamous cell carcinoma (SCC) is the second most common type of cancer (1). Despite recognition
of ultraviolet exposure as a preventable risk factor for SCC, there has been a 100% increase in keratinocyte carcinomas (KCs), including SCC and basal cell carcinoma (BCC), and an increase in the SCC to BCC ratio from
1992 to 2012 in the United States population (2). SCC is associated with significant morbidity including ulceration and disfigurement, and a mortality rate similar to that of melanoma, particularly in solid organ transplant
recipients (3–5). Treatments for SCC include surgery and radiation for localized disease, and chemotherapy, targeted therapy, and immunotherapy for unresectable and metastatic cancer (5–8). In addition to their side effects,
the treatments for SCC and BCC represent a rising public health challenge, with more than $1 billion in total
annual cost in the United States (9). Therefore, skin cancer prevention is an urgent unmet need.
Actinic keratosis (AK) is a common precursor to SCC that develops in sun-damaged skin (10). Treatment for AKs is recommended due to their premalignant nature (11). While an individual AK is estimated
to have a less than 1% chance of progressing to SCC within 1 year, the majority of SCCs arise from existing
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AKs, highlighting their shared origin (12–14). Without intervention, patients with numerous AKs have a
relatively high cumulative risk of developing skin cancer (11). Treatment options for AKs include therapies directed against individual lesions, such as cryotherapy, and field treatments including photodynamic
therapy (PDT) and topical 5-fluorouracil (5-FU), imiquimod, diclofenac, and ingenol mebutate (15–17).
Although they are effective in eliminating AKs, the ability of these cytotoxic and innate-immune-activating
agents to prevent SCC in the long term is unknown. The only agent that has been shown to reduce the risk
of SCC after treatment cessation is 5-FU, and this benefit is no longer apparent 2 years after treatment (18).
Previously, we discovered calcipotriol plus 5-FU combination as a novel topical immunotherapy for
AKs (19). Calcipotriol is a low-calcemic vitamin D analog that is FDA approved for the treatment of psoriasis (20). Calcipotriol induces the expression of thymic stromal lymphopoietin (TSLP) cytokine in keratinocytes (19, 21, 22). In a randomized, double-blind clinical trial with 130 participants, we demonstrated
that a 4-day course of 0.005% calcipotriol ointment plus 5% 5-FU cream was superior to Vaseline plus
5-FU in eliminating AKs (19). Calcipotriol plus 5-FU treatment induced the expression of TSLP which,
together with cellular stress signals from the premalignant keratinocytes, led to a robust CD4+ T cell immunity against AKs and thus their elimination (19). While our clinical trial provided evidence that calcipotriol
plus 5-FU combination is an effective immunotherapy for skin cancer precursors, it remained unknown
whether this reduction in AKs would translate into a decreased risk of SCC over time.
Herein, we investigated the effectiveness of topical calcipotriol plus 5-FU treatment in preventing
SCC development. We analyzed the clinical data and tissue samples obtained from the participants
in our randomized controlled trial followed for over 1,500 days after treatment. We determined that a
short course of calcipotriol plus 5-FU was associated with the induction of a tissue-resident memory
T (Trm) cell response and a decrease in risk of SCC development on the face and scalp over a 3-year
period following treatment.

Results
Study population. Among the 130 patients who completed the randomized controlled trial, 64 were in
the calcipotriol plus 5-FU test arm and 66 were in the Vaseline plus 5-FU control arm. Of these, 33
patients (20 in the test arm and 13 in the control arm) were excluded from the present study because
of loss to follow-up due to death, lack of subsequent dermatologic care, or inability to retrieve outside
records. An additional 11 participants (3 in test arm and 8 in control arm) were excluded because of
the use of immunosuppressive agents during the follow-up period. Two participants in the test arm
had 536 and 889 days of follow-up before their death and were excluded from the 2/3–year and 3-year
analyses, respectively. Thus, the final study population included 86 participants (41 test and 45 control)
for 1-year outcomes, 85 participants (40 test and 45 control) for 2-year outcomes, and 84 participants
(39 test and 45 control) for 3-year outcomes (Figure 1). For outcomes limited to the treated face and
scalp, 72 participants (32 test and 40 control) were eligible.
Demographic and clinical characteristics of test and control study participants (n = 86) were similar
(Table 1). Participants in each treatment arm were similar in terms of age, skin type, and days of follow-up
before and after the clinical trial. In both treatment arms, 56% of participants had a KC diagnosis within
the period of interest before the trial. More specifically, 17 patients (41%) in the test arm and 16 patients
(36%) in the control arm had a history of SCC during the period of interest. Nearly half of the participants
also had a history of AK field treatment with 5-FU and/or PDT within the period of interest before the
trial (Table 1). The treatment groups had similar AK counts on the scalp, right upper extremity (RUE), and
left upper extremity (LUE) prior to initiating the trial (Table 1). The only statistically significant difference
between groups was a higher baseline number of AKs on the face in the test group (Table 1). Demographic
and clinical characteristics of the study participants who received treatment on the face and/or scalp (n
= 72) were also similar between the 2 groups except for higher baseline AK counts on the face of the test
group (Supplemental Table 1). There was no significant difference in the AK treatments that participants
received after the trial (Supplemental Table 2).
Study outcomes. To investigate whether optimal immune activation upon calcipotriol plus 5-FU treatment was associated with long-term protection from skin cancer, we first examined whether the treatment-induced erythema extent and intensity on the treated anatomical sites could be used as a determinant of the immune activation against AKs (19). Among the prospective cohort study participants, the
inflammation grades in the AK biopsies obtained 1 day after the treatment (Supplemental Figure 1) were
insight.jci.org   https://doi.org/10.1172/jci.insight.125476
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Figure 1. CONSORT diagram of clinical trial followed by prospective cohort study. Flow chart illustrates the number
of clinical trial participants randomized to each treatment group who were included in analyses at 1, 2, and 3 years
after treatment. Participants were excluded if they had fewer than 365 days of follow-up after the clinical trial or were
immunosuppressed due to a medical condition or therapy during the follow-up period.

tightly correlated with the erythema extent and intensity scores of the biopsied anatomical sites across
the test and control groups (P < 0.0001; Figure 2, A and B). Next, we found that erythema extent and
intensity were significantly higher on the treated face and scalp of the test compared with the control
group (Figure 2, C and D). In contrast, no significant difference in erythema extent or intensity was
observed between treatment groups on the treated upper extremities in our prospective cohort study participants (Figure 2, C and D). The high erythema scores on the face and scalp correlated with an intense
CD4+ T cell response, which was much more robust than the CD8+ T cell response, and the induction
of CD69+ and CD103+ Trm cells against the AKs on the test group’s face and scalp immediately after
calcipotriol plus 5-FU treatment (Figure 2, E and F, and Supplemental Figure 2). Interestingly, CD4+
T cells colocalized with the premalignant keratinocytes in AKs, while CD8+ T cells were mostly found
deep in the dermis, suggesting a bystander role for CD8+ T cells in the immunity induced by calcipotriol
plus 5-FU against AKs (Supplemental Figure 3 and ref. 19).
Consistent with this robust immune activation, Kaplan-Meier analysis revealed that a higher proportion of participants who received calcipotriol plus 5-FU treatment on their face and scalp remained SCCfree on these anatomical sites throughout the entire longitudinal study period, which reached greater than
1,500 days after the clinical trial initiation date. However, this trend did not reach statistical significance (P
= 0.0765; Figure 3A). Importantly, only 2 out of 30 participants in the calcipotriol plus 5-FU group developed SCC on their treated face and scalp within 3 years following the clinical trial compared with 11 out of
40 in the control group (P = 0.032), corresponding to a hazard ratio (HR) of 0.215 (95% CI: 0.048–0.972;
Table 2). There was no statistical difference in the percentage of patients in each group who developed SCC
within 1 or 2 years after the trial, likely due to the paucity of events (Table 2).
In contrast to SCC risk reduction on the face and scalp, there was no significant difference in the
percentage of participants who developed SCC or BCC across all the treated anatomical sites at 1, 2,
or 3 years after the trial (Supplemental Figure 4 and Supplemental Table 3). In addition, there was no
significant difference in the percentage of participants who developed BCC on their treated face and/
or scalp within 1, 2 or 3 years after the trial (Table 2). Likewise, a similar proportion of participants in
both groups remained without a BCC diagnosis on their treated face and/or scalp over the >1,500-day
follow-up period after the trial (P = 0.1936; Supplemental Figure 5).
To explain the lack of treatment efficacy against BCC, we examined the immune microenvironment of
BCCs that had been biopsied during routine clinical follow-up after the trial. In contrast to the substantial
insight.jci.org   https://doi.org/10.1172/jci.insight.125476
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Table 1. Baseline demographic and clinical characteristics
Calcipotriol + 5-FU (n = 41) Vaseline + 5-FU (n = 45)

Age, mean (SD), y
(Range)
Sex, n (%)

P value

68 (7)
(56–86)

69 (8)
(52–84)

0.596

Male
Female

29 (71)
12 (29)

36 (80)
9 (20)

Face
Scalp
RUE
LUE

26 (63)
18 (44)
16 (39)
21 (51)

34 (76)
24 (53)
17 (38)
20 (44)

0.221
0.382
0.906
0.530

Face
Scalp
RUE
LUE

18 (11)
23 (17)
13 (10.5)
12 (8)

15 (12)
20.5 (21.5)
14 (21)
11.5 (19)

0.046
0.565
0.499
0.783
0.259

I
II
III

6 (15)
27 (66)
8 (19)
720 (473)
(8–1,366)
1,282 (190)
(536–1,531)

13 (29)
26 (58)
6 (13)
805 (391)
(24–1,331)
1,263 (138)
(1,016–1,534)

0
≥1

26 (63)
15 (37)

29 (64)
16 (36)

0
≥1

24 (59)
17 (41)

29 (64)
16 (36)

0
≥1

18 (44)
23 (56)

20 (44)
25 (56)

0
≥1

27 (66)
14 (34)

26 (58)
19 (42)

0
≥1

25 (61)
16 (39)

28 (62)
17 (38)

0.318

Anatomical Sites Treated, n (%)

Baseline AK Count on Each Anatomical Site,
median (interquartile range)

Fitzpatrick Skin Type, n (%)

Follow-up before trial, mean (SD), d
(Range)
Follow-up after trial, mean (SD), d
(Range)
History of BCC before trial, n (%)

History of SCC before trial, n (%)

History of KC before trial, n (%)

0.365
0.583
0.920

0.574

0.960

History of 5-FU treatment before trial, n (%)

History of PDT treatment before trial, n (%)

0.736

0.851

5-FU, 5-fluorouracil; RUE, right upper extremity; LUE, left upper extremity; AK, actinic keratosis; BCC, basal cell carcinoma; SCC, squamous cell carcinoma;
KC, keratinocyte cancer; PDT, photodynamic therapy.

T cell infiltration detected in SCC, BCC from the same participant that developed on the same anatomical
site (face) and was biopsied at the same time had minimal T cell infiltrate, which predominantly consisted
of Foxp3+ regulatory T cells (Supplemental Figure 6). A T cell–poor tumor microenvironment was present
in BCCs of the face and scalp in both the test and control participants compared with their AK-SCC spectrum counterparts after the trial (Supplemental Figure 7).
Trm cell persistence in the calcipotriol plus 5-FU–treated skin. We performed immunostaining on the skin
biopsies obtained for clinical diagnostic purposes after the trial to determine the contribution of the
Trm cells to the chemopreventive effect of calcipotriol plus 5-FU treatment on the face and scalp. We
obtained tissue sections from 22 participants who had been treated on the face or scalp during the trial
and had AK-SCC spectrum biopsies from the treated sites obtained during routine clinic visits after the
insight.jci.org   https://doi.org/10.1172/jci.insight.125476
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Figure 2. Immune activation, erythema, and Trm induction by calcipotriol plus 5-FU treatment. (A and B) The inflammation grades of AK biopsies are compared with the (A) erythema extent and (B) erythema intensity on the biopsied
anatomical sites 1 day after completion of a 4-day treatment course. Note that the data include all participants in the
prospective cohort study who contributed an AK biopsy during the clinical trial. P values were calculated by Fisher’s
exact test. (C) Stacked bar chart compares the distribution of participants’ erythema extent in each treatment group for
each treated anatomical site. **P < 0.001, ***P < 0.0001 by Fisher’s exact test. ns, not significant. (D) Stacked bar chart
compares the distribution of participants’ erythema intensity in each treatment group for each treated anatomical site.
*P < 0.01, **P < 0.001, ***P < 0.0001 by Fisher’s exact test. ns, not significant. (E) Representative histologic images show
AKs that were biopsied on the face and scalp 1 day after treatment with calcipotriol plus 5-FU (C+F) or Vaseline plus 5-FU
(V+F). Tissue samples were stained with H&E and with antibodies against CD3 plus CD4, CD69, or CD103 to detect induction of CD4+ T cell immunity and CD69+CD103+ Trm cells in the lesional skin. Erythema intensity associated with the site of
the biopsies: face C+F, 3; face V+F, 0; scalp C+F, 2; scalp V+F, 1. Scale bars: 100 μm. (F) CD4+ T, CD8+ T, CD103+CD4+ Trm, and
CD103+CD8+ Trm cells are quantified across 24 high-power field (hpf) images of 3 test (C+F) AKs and 20 hpf images of 3
control (V+F) AKs biopsied 1 day after treatment completion. **P < 0.001, ***P < 0.0001 by Wilcoxon’s rank-sum test.

trial. Blinded analysis revealed markedly increased epidermal CD4+ Trm (7.4 versus 2 cells per high-power field [hpf] on average, P = 0.0028) and CD8+ Trm cells (3.3 versus 1.1 cells per hpf on average, P =
0.0227) in the perilesional normal skin of the test group compared with control group (Figure 3, B and
C). As expected, the majority of epidermal T cells were CD69+ and/or CD103+, confirming their Trm
status (Supplemental Figure 8 and ref. 23).

insight.jci.org   https://doi.org/10.1172/jci.insight.125476
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Figure 3. Proportion of SCC-free
participants on the treated face
and scalp over time and the
accompanying Trm cell persistence
in the skin. (A) Kaplan-Meier
analysis shows that at any given
time over more than 1,500 days
of follow-up, a higher proportion
of participants in the calcipotriol
plus 5-FU treatment arm remained
free of squamous cell carcinoma
(SCC) on the treated face and scalp
compared with controls. This trend
approaches statistical significance.
(B) Representative immunostaining
images depict epidermal CD4+ and
CD8+ Trm cells in the perilesional
skin regions of AK-SCC spectrum
biopsies obtained from the face
and scalp of the participants after
trial (arrows point to epidermal
CD4+ Trm cells). Scale bar: 100 μm.
(C) Bar graphs show the number of
epidermal CD4+ and CD8+ Trm cells
in the perilesional normal skin from
22 participants, counted blindly and
averaged across 10 random hpf per
sample. Note that every AK-SCC
spectrum biopsy that was obtained
from the face and scalp of the participants during the >3-year period
after trial completion was included
in this analysis. P values were calculated by Wilcoxon’s rank-sum test.

Discussion
Our prospective cohort study has revealed that a 4-day course of calcipotriol plus 5-FU immunotherapy,
which effectively eliminated AKs in a double-blind randomized controlled trial (19), is associated with a
reduced long-term risk of SCC. Prior to our findings, it had been reported that a 4-week course of topical 5-FU monotherapy for AK field treatment reduces SCC risk on the face and ears at 1 year following
treatment; this effect, however, completely dissipates by 2 years (18). In contrast, our results suggest that
calcipotriol plus 5-FU treatment is effective in preventing SCC development on the face and scalp within
3 years after the treatment. This chemopreventive effect is associated with the induction of a long-lasting
T cell immunity in the skin. Therefore, our findings have broad implications by establishing a previously
unrecognized concept that an immunotherapeutic agent effective in eliminating precancerous lesions can
potentially yield long-term cancer prevention in humans.
By inducing the expression of TSLP in the skin, calcipotriol synergizes with the cytotoxic effects of
5-FU and leads to a robust CD4+ T cell immunity against skin carcinogenesis (19, 21, 22, 24). Accordingly,
AKs biopsied after this combination treatment exhibit increased TSLP expression and massive CD4+ T cell
infiltrates compared with AKs biopsied before treatment or after control treatment (19). Further, we have
demonstrated that CD4+ T cell immunity induced by calcipotriol plus 5-FU treatment generates Trm cells
associated with durable protection against SCC development. Following their induction by calcipotriol plus
insight.jci.org   https://doi.org/10.1172/jci.insight.125476
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Table 2. Cancer outcomes on treated face and scalp
Calcipotriol + 5-FU

Vaseline + 5-FU

Hazard Ratio

Type of lesion

Participants With ≥1
Lesion, n (%)

Participants With ≥1
Lesion, n (%)

HR (95% CI)

P value

KC
BCC
SCC

4 of 32 (13)
3 of 32 (9)
1 of 32 (3)

5 of 40 (13)
2 of 40 (5)
4 of 40 (10)

0.973 (0.261–3.625)
1.909 (0.319–11.427)
0.297 (0.033–2.654)

1.00
0.650
0.373

KC
BCC
SCC

6 of 31 (19)
5 of 31 (16)
2 of 31 (6)

10 of 40 (25)
4 of 40 (10)
7 of 40 (18)

0.741 (0.269–2.040)
1.673 (0.449–6.230)
0.335 (0.070–1.615)

0.775
0.490
0.282

KC
BCC
SCC

6 of 30 (20)
5 of 30 (17)
2 of 30 (7)

13 of 40 (33)
4 of 40 (10)
11 of 40 (28)

0.575 (0.219–1.514)
1.709 (0.459–6.363)
0.215 (0.048–0.972)

0.287
0.483
0.032

Year 1

Year 2

Year 3

5-FU, 5-fluorouracil; KC, keratinocyte cancer; BCC, basal cell carcinoma; SCC, squamous cell carcinoma.

5-FU treatment in the skin, CD4+ and CD8+ Trm cells persist in the epidermal niche. We propose that the
effectiveness of this immunological memory is evident by the reduced 3-year risk of SCC on the face and
scalp of our participants treated with calcipotriol plus 5-FU compared with Vaseline plus 5-FU.
The lack of protection against BCC development on the face and scalp after treatment with calcipotriol
plus 5-FU can be attributed to the immune-based mechanism of this combination therapy. First, the 4-day
course of calcipotriol plus 5-FU immunotherapy is directed against AKs, which carry a mutational burden
and an antigenic composition similar to SCC (25). This is distinct from the mutations found in BCC, particularly the driver mutations in the sonic hedgehog signaling pathway (25). As such, the lack of protection against
a genetically distinct cancer such as BCC could be anticipated given that the Trm cell response induced by
calcipotriol plus 5-FU combination is likely antigen-specific. Second, BCCs that developed in our participants
were immunologically cold and contained minimal effector T cell infiltrates compared with SCCs. This lack
of immunogenicity plus the recognized immunosuppressive microenvironment including regulatory T cells
surrounding BCCs (26) may contribute to the lack of efficacy observed for BCC immunoprevention.
Our results are consistent with previous murine studies in which treatment with calcipotriol was shown
to reduce the number of new epithelial neoplasms and delay the onset of malignant tumor development in
a TSLP-dependent manner (19, 24). Notably, the 4-day calcipotriol plus 5-FU treatment was most associated with a reduction in SCC development on the face and scalp, where it potently activated the adaptive
immune response. In contrast, calcipotriol plus 5-FU treatment caused a modest increase in erythema
extent and intensity on the upper extremities of the participants in our clinical trial (19). Erythema induced
by calcipotriol plus 5-FU treatment is a manifestation of immune activation against premalignant keratinocytes (19). The more robust immune induction in the face and scalp upon calcipotriol plus 5-FU treatment
is potentially due to a severely sun-damaged state of these anatomical sites resulting in a higher mutational
burden that could be more readily targeted by T cells (25). Another possible explanation for this observed
difference may relate to the higher penetration of topical medications into the skin of the face and scalp
compared with that of the upper extremities (27). Therefore, a longer calcipotriol plus 5-FU treatment
course may provide durable protection against SCC development on the upper extremities.
In conclusion, we report that a 4-day course of calcipotriol plus 5-FU immunotherapy directed against
AKs on the face and scalp reduces the risk of SCC 3 years following treatment. The higher number of
AKs on the face of the participants in the test group prior to the clinical trial suggests that participants in
the test group may have had more sun damage and been at higher risk of developing SCC on the face at
baseline, lending further support to the validity of our conclusions. A higher proportion of patients in the
calcipotriol plus 5-FU treatment group remained SCC-free on their face and scalp at any given time point
during the follow-up period compared with the control group. However, this trend did not reach statistical
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significance, likely due to our limited sample size and follow-up duration. Further studies are warranted
to determine the optimal calcipotriol plus 5-FU treatment duration required to induce a chemopreventive effect at all anatomical sites at risk for SCC development. In addition, longer follow-up is required
to determine whether the chemopreventive effect of calcipotriol plus 5-FU treatment extends beyond 3
years. Finally, it will be critical to examine the efficacy of calcipotriol plus 5-FU immunotherapy for skin
cancer prevention in high-risk populations including organ transplant recipients. Despite these limitations,
our study establishes calcipotriol plus 5-FU combination as a short, well-tolerated topical treatment with
the potential to reduce the incidence of SCC, therefore addressing a major public health problem. These
remarkable findings substantiate the use of immunotherapeutic agents with minimal side effects and high
efficacy against precancerous lesions in order to reduce the risk of cancer development and recurrence,
which may be broadly applicable to skin and internal malignancies.

Methods
Clinical study design
Clinical trial. The current study includes a post hoc analysis of a double-blind, randomized controlled trial,
which was conducted at Washington University Medical Center between October 2013 and March 2015
(ClinicalTrials.gov number NCT02019355; ref. 19). Study participants included 130 immunocompetent
adults with 4 to 15 actinic keratoses within a 25-cm2 area on the face, scalp, RUE, and/or LUE. Blinded
participants were randomized to self-administer a 4-day course of twice-daily 5% 5-FU cream mixed in
equal parts with either Vaseline or 0.005% calcipotriol ointment applied to the entire surface area of their
qualified anatomical sites. Clinical assessment for AK clearance, erythema, and adverse effects was performed on the day immediately after treatment (day 5) and at weeks 2, 4, and 8 (19). AK biopsies were
performed prior to treatment and 1 day following treatment completion.
Prospective cohort study patient selection. Postclinical trial study patient selection was performed between
August 2017 and December 2017. The duration of follow-up after the trial was calculated for each patient
as the number of days from the patient’s trial treatment start date to the most recent skin exam documented
in the patient’s electronic medical record. For patients who indicated via phone interview that they had
been diagnosed with skin cancer by a provider outside of the Washington University system, diagnoses
were confirmed by clinical records and pathology reports. Patients who had less than 365 days of follow-up
or who were immunocompromised due to a new medical condition or institution of an immunosuppressive
drug at any point after the trial were excluded from analysis.

Study assessment
Clinical data analysis. Data collection and analysis were performed at Washington University between September 2017 and September 2018. Demographic and clinical characteristics of the study population (age,
sex, Fitzpatrick skin type, baseline AK counts per anatomical site, AK treatment history, SCC and BCC
history) were extracted from medical records and trial data. A detailed skin cancer and AK treatment history was collected for the available follow-up period after clinical trial initiation. In order to compare baseline
skin cancer risk and AK treatment history between the 2 treatment groups prior to the trial, the same information was collected for a similar number of days before trial initiation (rounded to the nearest clinic visit).
Primary study outcomes included the presence or absence of a histopathologic diagnosis of primary SCC
(including invasive and in situ lesions), BCC, and any KC (SCC or BCC), located in any of the anatomical
sites (face, scalp, RUE, and LUE) that were treated during the clinical trial. Cancer outcomes were assessed
in a blinded manner at 1, 2, and 3 years following the clinical trial initiation date and were characterized as
binary variables (diagnosis of 0 versus ≥1 skin cancer in that category since the trial). The date of the first
SCC diagnosis following the clinical trial was recorded for time-to-event analysis.
Tissue analysis. Tissue analysis was performed at Massachusetts General Hospital between July 2018
and December 2018. To determine the inflammation grades and the induction of Trm cell formation following calcipotriol plus 5-FU versus Vaseline plus 5-FU treatment, we performed H&E and immunostaining of formalin-fixed paraffin-embedded 5-μm sections of the AK biopsy tissue obtained during the trial.
To determine whether Trm cells persisted in the skin, we evaluated lesional and perilesional tissue from all
trial participants who had been treated on the face and/or scalp during the trial and had an AK-SCC spectrum biopsy performed at the treated site during routine clinical follow-up at any time during the >3-year
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follow-up after the trial. For immunofluorescent staining, tissue sections were incubated with primary antibodies against CD3 (clone CD3-12, Abcam), CD4 (clone SP35, Spring Bioscience), CD8 (clone C8/144B,
Cell Signaling Technology), CD69 (clone FN50, Biolegend), and CD103 [clone EPR4166(2), Abcam] followed by secondary antibodies. All slides were counterstained with DAPI nuclear stain (Thermo Fisher
Scientific). CD4 and CD8 automated immunohistochemical staining was performed using a Ventana Ultra
automated immunostainer (Ventana Medical Systems). Cell counts were performed blindly on randomly
selected histological images at ×200 magnification (hpf).

Clinical study oversight
The clinical trial and prospective cohort study protocols were approved by the academic IRBs of Washington University in St. Louis, Missouri and Massachusetts General Hospital in Boston, Massachusetts. All
participants provided written informed consent to participate in the clinical trial and were contacted via
phone to obtain verbal informed consent for access to their protected health information (PHI) and tissue
samples for this prospective cohort study. The study was conceived, designed, initiated, and performed by
the academic investigators. The authors confirm the accuracy and completeness of the data and analysis
and the fidelity of the study to the protocol. All authors agreed to submit the manuscript for publication.

Statistics
Baseline demographic and clinical characteristics were characterized by mean and standard deviation for
continuous variables and by frequency distribution and percentage of total for categorical variables. SAS
9.4 (SAS Institute) was used to perform 2-sample Student’s t tests for continuous variables, Pearson’s χ2
tests and Fisher’s exact test for categorical variables, and time-to-event analysis for Kaplan-Meier curves.
Wilcoxon’s rank-sum test was used as the test of significance for T cell counts. A P value less than 0.05 was
considered significant.
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